GLP-1 medicines like Ozempic and Wegovy: side effects, what the difference actually is, and questions worth asking
Ozempic, Wegovy, Mounjaro, and Zepbound get discussed like they are interchangeable. They are not quite the same, the side effects are real, and the evidence behind them goes well beyond the scale.
Ozempic, Wegovy, Mounjaro, Zepbound: what is actually different
Ozempic and Wegovy are both semaglutide, the same molecule, made by the same company, at different doses and approved for different uses: Ozempic for type 2 diabetes, Wegovy for chronic weight management. Mounjaro and Zepbound are both tirzepatide, again the same molecule at different doses for diabetes versus weight management, made by a different company. Semaglutide works on one gut hormone receptor (GLP-1); tirzepatide works on two (GLP-1 and GIP), which is part of why tirzepatide has produced somewhat greater average weight loss in head-to-head-style trial comparisons. A doctor prescribing "off-label" or a compounded version of either is doing something meaningfully different from prescribing the FDA-approved product, in dose accuracy and in oversight.
How they work, and why the benefit is not just appetite
These medicines mimic gut hormones released after eating, which slow digestion, increase the feeling of fullness, and reduce appetite, typically producing 15 to 20 percent body weight loss in trials when combined with lifestyle support. What changed the guidelines is evidence that semaglutide also reduces heart attacks, strokes, and cardiovascular death in people with obesity and existing heart disease (the SELECT trial), independent of how much weight was lost. This is why a clinician might recommend one of these medicines specifically for your heart risk, not only for weight.
The side effects worth knowing about
- Nausea, vomiting, and diarrhea are the most common, especially when starting or increasing the dose; starting low and increasing slowly reduces this significantly.
- Constipation is also common.
- Gallstones occur more often, likely related to rapid weight loss itself.
- Pancreatitis is a rare but serious risk to be aware of.
- Muscle loss alongside fat loss is a real concern with rapid weight loss on any method; strength training and adequate protein intake during treatment are recommended to protect muscle mass.
- These medicines are not recommended during pregnancy, and there are specific precautions for people with a personal or family history of certain thyroid cancers.
Most side effects are worst in the first weeks after starting or increasing a dose and improve with time.
Questions worth asking before starting one
- Is this the FDA-approved product, filled at a licensed pharmacy, not a compounded version?
- Is this being prescribed for diabetes, weight, cardiovascular risk, or more than one?
- What is the plan for protecting muscle mass while I am on it?
- What is the long-term plan if I lose weight and want to stop, since weight regain after stopping is common without a plan?
- Do you monitor for gallbladder symptoms or signs of pancreatitis?
Finding a doctor who prescribes these medicines responsibly
Every clinician in our weight loss doctors list has attested that they do not sell compounded semaglutide or tirzepatide, prescribes the FDA-approved product, and follows guideline-based obesity care. No patient reviews, no star ratings. Search near you by specialty and city.
Common questions
Is compounded semaglutide the same as Ozempic or Wegovy?
No. Compounded versions are not FDA-approved, are not verified for purity or exact dose, and are not made by the original manufacturer. Guideline-based practices prescribe the approved product through a licensed pharmacy.
Do I have to stay on a GLP-1 medicine forever?
Most people who stop regain a significant portion of the weight, since the medicine treats an ongoing biological drive to eat, not a one-time problem. Whether to plan for long-term use is a conversation to have with your prescriber before starting.
References
- SELECT trial: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (NEJM 2023), NEJM (2023)
Why this matters
Good specialist care follows the guidelines. A directory that verifies that, rather than counting stars, changes who you end up in front of.
DoctorDirectory.ai is different on purpose. Every clinician is verified against the federal license registry, screened across their website, social accounts, board actions, and news, and signs a dated attestation to the major society guidelines that renews every year. Websites are re-checked monthly and listings are audited at random. Nothing a clinician or advertiser pays for changes who passes or who ranks. And there are no patient reviews to buy, bulk-post, or weaponize. That is what a vetted directory looks like, and it is what a healthcare system running low on trust needs more of.
For patients
Find the right doctor, then tell someone.
Search by condition and city. Every result is licensed, board-certified, and on record for evidence-based care. If a friend or family member is choosing a doctor, send them here before they read a single star rating. The more people who expect this standard, the more clinicians will meet it.
For clinicians and the medical community
Vetting and guardrails are how we earn trust back.
A license proves training. It does not tell a patient who sells peptides, who tells families to skip vaccines, or who quietly lost a license in another state. Directories that verify, attest, re-check, and remove are the guardrails the profession has been missing. If you practice from the evidence, put your name to it where patients can see it, and ask your colleagues to do the same.
